So...
MSB now has a Type A meeting in 30 days to discuss getting approval for remestemcel-l in paediatric patients on the condition that it will conduct a randomised trial in adults.
If that's not approved, is there anything else Mesoblast can do in this situation or does paediatric use then get delayed for years until a randomised control study is complete in adults?
What are the implications if;
- There is lower efficacy in adults? Will that matter?
- In what context can remestemcel-l trial in COVID patients be used instead of the need for a brand new study? Or is that not possible at all?
- Forums
- ASX - By Stock
- MSB
- MSB to dispute FDA finding in Type A meeting
MSB to dispute FDA finding in Type A meeting, page-110
-
-
- There are more pages in this discussion • 908 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
0.005(0.43%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.15 | $1.20 | $1.15 | $2.061M | 1.760M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
32 | 42021 | $1.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 19878 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
25 | 31959 | 1.165 |
23 | 95658 | 1.160 |
17 | 96515 | 1.155 |
22 | 243742 | 1.150 |
8 | 146091 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 33686 | 9 |
1.175 | 83074 | 12 |
1.180 | 88704 | 11 |
1.185 | 99302 | 10 |
1.190 | 77351 | 8 |
Last trade - 12.42pm 16/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |